Citigroup’s Calidi Biotherapeutics CLDI Stock Holding History

Citigroup’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3	Buy	14 +13	+1,300%	+$10	﹤0.01%	5804
2025 Q4	$1	Buy	+1	New	+$1	﹤0.01%	5960

Other funds holding CLDI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's CLDI Position: Q1 2026 in Review

Citigroup increased its Calidi Biotherapeutics (CLDI) stake by 1,300% in Q1 2026, buying an estimated $10 and bringing the position to 14 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #5804.

Citigroup first reported a position in CLDI in Q4 2025 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

Citigroup held 14 shares of Calidi Biotherapeutics worth $3 as of Q1 2026.
Citigroup bought 13 Calidi Biotherapeutics shares in Q1 2026, an estimated $10.
Calidi Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5804 holding.
Citigroup first reported a position in Calidi Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.